- Women with high blood pressure during pregnancy had lower blood pressure nine months later if their blood pressure was more tightly controlled the first few weeks after delivery, compared to women who received usual postpartum care.
- In the United Kingdom, usual postpartum care consists of an initial office visit with the family physician or midwife at 5-10 days after delivery and a follow-up at around 6- 8 weeks after giving birth, which the trial suggests may miss a critical window for early blood pressure optimization.
- Improving blood pressure control after delivery also resulted in fewer postpartum hospital readmissions for high blood pressure and long-term beneficial changes in the structure and function of the heart and blood vessels of the women who had received the intervention.
Embargoed until 3:30 p.m. ET, Saturday, Nov. 11, 2023
PHILADELPHIA, Nov. 11, 2023 — Women with high blood pressure during pregnancy had long-term blood pressure and cardiac benefits if their blood pressure was carefully controlled for the first few weeks after having a baby, according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2023. The meeting, Nov. 11-13, in Philadelphia, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. The full manuscript is also simultaneously published today in The Journal of the American Medical Association.
“The heart undergoes significant changes during any pregnancy to cope with the increased circulatory demands of the growing baby, and these changes are much more profound during a hypertensive pregnancy, because of the increased stress of the pregnancy,” said lead study author Paul Leeson, M.B., B.Chir., Ph.D., a professor of cardiovascular medicine at the University of Oxford in the United Kingdom. “Women who have had uncontrolled high blood pressure during pregnancy are at significantly greater risk of complications with their heart longer term. One-third develop hypertension again within 10 years of pregnancy and their risk of early heart attack and stroke are doubled.”
In this prospective, randomized trial conducted in the U.K., researchers investigated the effects of improving blood pressure control immediately after pregnancy on long-term blood pressure levels.
This study included 220 new mothers who had high blood pressure during pregnancy and still needed medication for high blood pressure after giving birth.
Half of the participants were randomly assigned to the group that received a wireless blood pressure monitor and asked to send daily blood pressure readings via a phone app to the study doctors. The phone and app were connected to the blood pressure monitor via Bluetooth, and blood pressure measures were automatically uploaded to the app and automatically shared with the study doctors. The app sent automated prompts to the participants based on their blood pressure levels — to either repeat a reading or, if the reading was in a range that needed changes to their blood pressure medication, advised them to contact their doctor in the trial. The doctors then advised participants via phone or video call about how to adjust their medication to make sure their blood pressure remained below 140/90 mm Hg.
The remaining half of the participants received usual postpartum care, which, in the U.K., involves an office visit with the family physician or midwife 5-10 days after delivery and another at 6-8 weeks after giving birth.
“The trial suggests the timing of this second appointment may miss a critical window for early blood pressure optimization,” Leeson said. “While this visit includes a blood pressure examination and participants are likely to be on blood pressure medication until their blood pressure is back in a normal range, their blood pressure will not be as carefully monitored and medication will not be as tightly adjusted as in the intervention group of the trial.”
The trial results found:
- Nine months after delivery, the women in the intervention group had an average clinic blood pressure of 126/82 mm Hg, compared to 131/86 mm Hg for the women who received usual care.
- This long-term reduction in blood pressure was seen even though 70% of the women in both groups no longer needed high blood pressure medication by around six weeks after delivery. Participants in the intervention group had a median duration of treatment with anti-hypertensive medication of 39 days.
- The effect on lowering high blood pressure persisted for eight to nine months after participants stopped taking high blood pressure medication.
- Fewer women who received the intervention needed to go back into the hospital in the first three weeks after delivery as a result of high blood pressure.
“We were surprised by the size and consistency of the blood pressure reduction in the women who received the intervention. The benefits started to emerge within the first week or two after pregnancy, and the effect on blood pressure persisted after the medication was stopped,” Leeson said.
“A 5-10 mm Hg reduction in blood pressure is typically associated with a 20% reduction in longer-term cardiovascular risk,” he added. “If the reduction in blood pressure we observed at nine months is sustained long-term, this could slow progression to needing treatment for hypertension by an average of up to a decade.”
Approximately 90% of participants agreed to have the researchers also perform cardiac magnetic resonance imaging and echocardiography on them at nine months postpartum. Women who had received the tighter blood pressure control after delivery showed clear improvements in the structure and function of the heart compared to women who had usual care.
Study details and background:
- Approximately 80% of the participants were white women, with an average age of 33 years.
- Approximately 65% of the study participants had just completed their 1st pregnancy, 30% had completed their second pregnancy and 5% had completed their 3rd pregnancy.
Study limitations included that the study was conducted at a single research center, meaning that the intervention may need to be modified before being repeated at multiple centers, and that the research team delivering the study intervention knew who had the self-monitoring devices, which may bias results. To overcome this potential for bias, the researchers ensured that blood pressure measurements were digitally collected by the participants’ 24-hour blood pressure machines, which downloaded measurements and added them to the research database. This method was independent of the study team and mothers, and those who conducted the analysis were blinded to how the home blood pressure monitoring devices were allocated, Leeson said.
Future work will involve replicating the study in more racially and ethnically diverse patient populations in the U.K., identifying the optimal way to provide care after pregnancy and exploring the potential mechanisms of cardiac remodeling that may underpin the long-term lowering of blood pressure, Leeson said.
The 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults classifies stage 1 hypertension as having clinic top and bottom numbers greater than or equal to 130/80 mm Hg and stage 2 hypertension as having top and bottom numbers greater than or equal to 140/90 mm Hg.
Co-authors, disclosures and funding sources are listed in the abstract.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
- Multimedia is available on the right column of the release link https://newsroom.heart.org/news/improving-blood-pressure-control-after-pregnancy-had-long-term-cardiovascular-benefits?preview=a30ce98c3c9b40284314ba896e2e6e49
- After Nov. 11, view the abstract in the AHA Scientific Sessions 2023 Online Program Planner
- AHA news release: 1 in 2 patients had better blood pressure control after using remote, bilingual program (September 2023)
- AHA news release: Scheduled childbirth may greatly reduce preeclampsia, a leading cause of maternal death (April 2023)
- AHA Scientific Statement: Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association
- About Scientific Sessions 2023
- For more news at AHA Scientific Sessions 2023, follow us on X (formerly known as Twitter) @HeartNews, #AHA23
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective:
AHA Communications & Media Relations in Dallas:
For Public Inquiries: 1-800-AHA-USA1 (242-8721)